Assessment of Predicted LET and Dosimetry in Relation to Treatment-Related Injury Following Proton Therapy for Primary Pediatric Central Nervous System, Base of Skull, and Malignancies


About this study

The purpose of this study is to evaluate LET-based modeling as an early and accurate predictor for white-matter changes as identified on MRI and DTI in pediatric patients with primary central nervous system and skull base malignancies following proton beam therapy

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients must have histologically confirmed central nervous system of skull base tumors.
  • ≤ 21 years of age at the date of consent.
  • Patient is going to undergo CNS or base of skull proton beam therapy.

Exclusion Criteria:

  • Patients > 21 years of age.
  • Patients who have received prior therapeutic radiotherapy to the primary brain tumor site.
  • Patients who are unable to maintain follow-up through the Phoenix Children’s Hospital and Mayo Clinic Arizona.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Tamara Vern-Gross, D.O.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information


Publications are currently not available

Mayo Clinic Footer